Casey M Theriot

List of Publications by Year in Descending Order

46 papers	3,077 citations	23 h-index	52 g-index
52 ext. papers	4,415 ext. citations	8.5 avg, IF	5.84 L-index

#	Paper	IF	Citations
46	Prolonged oral antimicrobial administration prevents doxorubicin-induced loss of active intestinal stem cells.. *Gut Microbes*, **2022**, 14, 2018898	8.8	0
45	The Stickland Reaction Precursor -4-Hydroxy-l-Proline Differentially Impacts the Metabolism of Clostridioides difficile and Commensal .. *MSphere*, **2022**, e0092621	5	0
44	Mechanisms of Colonization Resistance Against Clostridioides difficile. *Journal of Infectious Diseases*, **2021**, 223, S194-S200	7	5
43	Clostridioides difficile exploits toxin-mediated inflammation to alter the host nutritional landscape and exclude competitors from the gut microbiota. *Nature Communications*, **2021**, 12, 462	17.4	26
42	Contribution of Inhibitory Metabolites and Competition for Nutrients to Colonization Resistance against by Commensal. *Microorganisms*, **2021**, 9,	4.9	3
41	Secondary bile acid ursodeoxycholic acid alters weight, the gut microbiota, and the bile acid pool in conventional mice. *PLoS ONE*, **2021**, 16, e0246161	3.7	2
40	bile salt hydrolase substrate specificity governs bacterial fitness and host colonization. *Proceedings of the National Academy of Sciences of the United States of America*, **2021**, 118,	11.5	23
39	Salicylanilide Analog Minimizes Relapse of Infection in Mice. *Journal of Medicinal Chemistry*, **2020**, 63, 6898-6908	8.3	5
38	Role of Microbiota-Derived Bile Acids in Enteric Infections. *Cell*, **2020**, 181, 1452-1454	56.2	8
37	Intestinal bile acids directly modulate the structure and function of TcdB toxin. *Proceedings of the National Academy of Sciences of the United States of America*, **2020**, 117, 6792-6800	11.5	18
36	Targeting of Clostridioides difficile Using Phage-Delivered CRISPR-Cas3 Antimicrobials. *MBio*, **2020**, 11,	7.8	50
35	Ursodeoxycholic Acid (UDCA) Mitigates the Host Inflammatory Response during Clostridioides difficile Infection by Altering Gut Bile Acids. *Infection and Immunity*, **2020**, 88,	3.7	17
34	Complete Genome Sequence of Lactobacillus johnsonii NCK2677, Isolated from Mice. *Microbiology Resource Announcements*, **2020**, 9,	1.3	1
33	Diversification of host bile acids by members of the gut microbiota. *Gut Microbes*, **2020**, 11, 158-171	8.8	95
32	Bile salt hydrolases: Gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract. *PLoS Pathogens*, **2019**, 15, e1007581	7.6	75
31	High-throughput amplicon sequencing of the full-length 16S rRNA gene with single-nucleotide resolution. *Nucleic Acids Research*, **2019**, 47, e103	20.1	155
30	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers. *PLoS ONE*, **2019**, 14, e0223378	3.7	5

29	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
28	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
27	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
26	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
25	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
24	Ceftiofur formulation differentially affects the intestinal drug concentration, resistance of fecal Escherichia coli, and the microbiome of steers **2019**, 14, e0223378		
23	Restoration of short chain fatty acid and bile acid metabolism following fecal microbiota transplantation in patients with recurrent Clostridium difficile infection. *Anaerobe*, **2018**, 53, 64-73	2.8	81
22	Beyond Structure: Defining the Function of the Gut Using Omic Approaches for Rational Design of Personalized Therapeutics. *MSystems*, **2018**, 3,	7.6	2
21	Shifts in the Gut Metabolome and Transcriptome throughout Colonization and Infection in a Mouse Model. *MSphere*, **2018**, 3,	5	54
20	A Small Molecule-Screening Pipeline to Evaluate the Therapeutic Potential of 2-Aminoimidazole Molecules Against. *Frontiers in Microbiology*, **2018**, 9, 1206	5.7	9
19	The Bile Salt Hydrolase Repertoire Reveals Niche-Specific Adaptation. *MSphere*, **2018**, 3,	5	43
18	Dosing Regimen of Enrofloxacin Impacts Intestinal Pharmacokinetics and the Fecal Microbiota in Steers. *Frontiers in Microbiology*, **2018**, 9, 2190	5.7	10
17	Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. *Science*, **2018**, 360,	33.3	503
16	Inhibition of spore germination, growth, and toxin activity of clinically relevant C.□difficile strains by gut microbiota derived secondary bile acids. *Anaerobe*, **2017**, 45, 86-100	2.8	94
15	Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291. *Journal of Visualized Experiments*, **2016**,	1.6	26
14	Antibiotic-Induced Alterations of the Gut Microbiota Alter Secondary Bile Acid Production and Allow for Clostridium difficile Spore Germination and Outgrowth in the Large Intestine. *MSphere*, **2016**, 1,	5	216
13	Impact of microbial derived secondary bile acids on colonization resistance against Clostridium difficile in the gastrointestinal tract. *Anaerobe*, **2016**, 41, 44-50	2.8	68
12	Effects of tigecycline and vancomycin administration on established Clostridium difficile infection. *Antimicrobial Agents and Chemotherapy*, **2015**, 59, 1596-604	5.9	10

11	Fecal Microbiota Transplantation Eliminates Clostridium difficile in a Murine Model of Relapsing Disease. *Infection and Immunity*, **2015**, 83, 3838-46	3.7	76
10	Interactions Between the Gastrointestinal Microbiome and Clostridium difficile. *Annual Review of Microbiology*, **2015**, 69, 445-61	17.5	167
9	Dynamics and establishment of Clostridium difficile infection in the murine gastrointestinal tract. *Infection and Immunity*, **2015**, 83, 934-41	3.7	100
8	Antibiotic-induced shifts in the mouse gut microbiome and metabolome increase susceptibility to Clostridium difficile infection. *Nature Communications*, **2014**, 5, 3114	17.4	568
7	Clostridium difficile-induced colitis in mice is independent of leukotrienes. *Anaerobe*, **2014**, 30, 90-8	2.8	7
6	Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. *Antimicrobial Agents and Chemotherapy*, **2014**, 58, 2767-74	5.9	53
5	Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection. *Gut Microbes*, **2014**, 5, 86-95	8.8	50
4	Improving the catalytic activity of hyperthermophilic Pyrococcus horikoshii prolidase for detoxification of organophosphorus nerve agents over a broad range of temperatures. *Archaea*, **2011**, 2011, 565127	2	23
3	Hydrolysis of organophosphorus compounds by microbial enzymes. *Applied Microbiology and Biotechnology*, **2011**, 89, 35-43	5.7	123
2	Cefoperazone-treated mice as an experimental platform to assess differential virulence of Clostridium difficile strains. *Gut Microbes*, **2011**, 2, 326-34	8.8	113
1	The interplay between microbiome dynamics and pathogen dynamics in a murine model of Clostridium difficile Infection. *Gut Microbes*, **2011**, 2, 145-58	8.8	192